Guengerich F P
Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, USA.
Adv Pharmacol. 1997;43:7-35. doi: 10.1016/s1054-3589(08)60200-8.
Many adverse drug-drug interactions are attributable to pharmacokinetic problems and can be understood in terms of alterations of P450-catalyzed reactions. Much is now known about the human P450 enzymes and what they do, and it has been possible to apply this information to issues related to practical problems. A relatively small subset of the total number of human P450s appears to be responsible for a large fraction of the oxidation of drugs. The three major reasons for drug-drug interactions involving the P450s are induction, inhibition, and possibly stimulation, with inhibition appearing to be the most important in terms of known clinical problems. With the available knowledge of human P450s and reagents, it is possible to do in vitro experiments with drugs and make useful predictions. The results can be tested in vivo, again using assays based on our knowledge of human P450s. This approach has the capability of not only improving predictions about which drugs might show serious interaction problems, but also decreasing the number of in vivo interaction studies that must be performed. These approaches should improve with further refinement and technical advances.
许多不良药物相互作用可归因于药代动力学问题,并且可以从细胞色素P450催化反应的改变方面来理解。现在人们对人类细胞色素P450酶及其作用了解很多,并且已经能够将这些信息应用于与实际问题相关的议题。人类细胞色素P450总数中相对较小的一部分似乎负责大部分药物的氧化。涉及细胞色素P450的药物相互作用的三个主要原因是诱导、抑制,可能还有刺激,就已知的临床问题而言,抑制似乎是最重要的。凭借现有的人类细胞色素P450和试剂知识,有可能用药物进行体外实验并做出有用的预测。结果可以在体内进行测试,同样使用基于我们对人类细胞色素P450的了解的检测方法。这种方法不仅能够改进对哪些药物可能出现严重相互作用问题的预测,还能减少必须进行的体内相互作用研究的数量。随着进一步的完善和技术进步,这些方法应该会得到改进。